Immunotherapy for Nasopharyngeal Carcinoma

Bossi, Paolo; Gurizzan, Cristina; Chan, Anthony

doi:10.1001/jama.2023.22465

Cited by 6 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 41 Immunotherapy, widely implemented in managing diverse malignancies such as kidney cancer, endometrial cancer, lung cancer, and nasopharyngeal carcinoma, has attained substantial efficacy, often accompanied by a reduced incidence of adverse effects. 42 , 43 , 44 , 45 Notably, clinicians have observed that only a subset of patients exhibit responsiveness to immunotherapy. Presently, researchers suggest that this variability in response may be attributable to factors such as tumour type, the patient's immune status, and additional variables, yet the biological underpinnings of this phenomenon continue to elude full understanding.…”

Section: Discussionmentioning

confidence: 99%

Deciphering lung adenocarcinoma prognosis and immunotherapy response through an AI‐driven stemness‐related gene signature

Ye,

Hongting,

Zhuang

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is a leading cause of cancer‐related deaths, and improving prognostic accuracy is vital for personalised treatment approaches, especially in the context of immunotherapy. In this study, we constructed an artificial intelligence (AI)‐driven stemness‐related gene signature (SRS) that deciphered LUAD prognosis and immunotherapy response. CytoTRACE analysis of single‐cell RNA sequencing data identified genes associated with stemness in LUAD epithelial cells. An AI network integrating traditional regression, machine learning, and deep learning algorithms constructed the SRS based on genes associated with stemness. Subsequently, we conducted a comprehensive exploration of the connection between SRS and both intrinsic and extrinsic immune environments using multi‐omics data. Experimental validation through siRNA knockdown in LUAD cell lines, followed by assessments of proliferation, migration, and invasion, confirmed the functional role of CKS1B, a top SRS gene. The SRS demonstrated high precision in predicting LUAD prognosis and likelihood of benefiting from immunotherapy. High‐risk groups classified by the SRS exhibited decreased immunogenicity and reduced immune cell infiltration, indicating challenges for immunotherapy. Conversely, in vitro experiments revealed CKS1B knockdown significantly impaired aggressive cancer phenotypes like proliferation, migration, and invasion of LUAD cells, highlighting its pivotal role. These results underscore a close association between stemness and tumour immunity, offering predictive insights into the immune landscape and immunotherapy responses in LUAD. The newly established SRS holds promise as a valuable tool for selecting LUAD populations likely to benefit from future clinical stratification efforts.

show abstract

Section: Discussionmentioning

confidence: 99%

Deciphering lung adenocarcinoma prognosis and immunotherapy response through an AI‐driven stemness‐related gene signature

Ye,

Hongting,

Zhuang

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study

Min,

Liu,

Wei

et al. 2024

Oral Oncology

View full text Add to dashboard Cite

Exploring cellular diversity in lung adenocarcinoma epithelium: Advancing prognostic methods and immunotherapeutic strategies

Zhang,

Cui,

Mei

et al. 2024

Cell Proliferation

View full text Add to dashboard Cite

Immunotherapy has brought significant advancements in the treatment of lung adenocarcinoma (LUAD), but identifying suitable candidates remains challenging. In this study, we investigated tumour cell heterogeneity using extensive single‐cell data and explored the impact of different tumour cell cluster abundances on immunotherapy in the POPLAR and OAK immunotherapy cohorts. Notably, we found a significant correlation between CKS1B+ tumour cell abundance and treatment response, as well as stemness potential. Leveraging marker genes from the CKS1B+ tumour cell cluster, we employed machine learning algorithms to establish a prognostic and immunotherapeutic signature (PIS) for LUAD. In multiple cohorts, PIS outperformed 144 previously published signatures in predicting LUAD prognosis. Importantly, PIS reliably predicted genomic alterations, chemotherapy sensitivity and immunotherapy responses. Immunohistochemistry validated lower expression of immune markers in the low‐PIS group, while in vitro experiments underscored the role of the key gene PSMB7 in LUAD progression. In conclusion, PIS represents a novel biomarker facilitating the selection of suitable LUAD patients for immunotherapy, ultimately improving prognosis and guiding clinical decisions.

show abstract

Immunotherapy for Nasopharyngeal Carcinoma

Cited by 6 publications

References 13 publications

Deciphering lung adenocarcinoma prognosis and immunotherapy response through an AI‐driven stemness‐related gene signature

Deciphering lung adenocarcinoma prognosis and immunotherapy response through an AI‐driven stemness‐related gene signature

Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study

Exploring cellular diversity in lung adenocarcinoma epithelium: Advancing prognostic methods and immunotherapeutic strategies

Contact Info

Product

Resources

About